|
Major Failure of Drug Approval Process.
Worried patients should not quit Avandia on their own and
should discuss concerns with their doctors, wrote Drs. Bruce
Psaty and Curt Furberg in an editorial in the New England
Journal. Psaty is with the University of Washington in Seattle
and Furberg is with Wake Forest University.
However, to the extent that the new analysis shows valid
risks, the drug "represents a major failure of the drug-use
and drug-approval processes in the United States," they
said.
When the drug was approved, "evidence was at best mixed"
on its benefit, wrote the two doctors. Both have been frequent
critics of the FDA's failure to spot dangers in the drug approval
process and its conduct in the case involving Vioxx. The popular
arthritis medicine sold by Merck & Co. was taken off the
market in 2004 when heart problems came to light after it
had been taken by millions of people
Several experts said Avandia was another example of the FDA
failing to detect a safety problem early enough.
The report on the diabetes drug's risks follow Glaxo's $2.5
million settlement of a lawsuit filed by former New York Attorney
General Eliot Spitzer over the release of data on the safety
and effectiveness of its drugs. Spitzer, now New York governor,
accused Glaxo of fraudulently withholding some results of
studies that had examined the safety of prescribing the antidepressant
Paxil to children
|